Ratings by H.C. Wainwright (Matt Caufield)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/1/2026 | DiaMedica Therapeutics Inc. | DMAC | Maintain | Buy (Buy) |
|
Details | ||
| 3/18/2026 | Aldeyra Therapeutics | ALDX | Downgrade | Neutral (Buy) |
1.24 (2.02) |
62.9% | Details | |
| 11/17/2025 | Adverum Biotechnologies | ADVM | Downgrade | Neutral (Buy) |
4.29 (4.36) |
1.63% | Details | |
| 10/20/2025 | Tarsus Pharmaceuticals | TARS | Maintain | Buy (N/A) |
|
Details | ||
| 9/23/2025 | Adverum Biotechnologies | ADVM | Maintain | Buy (Buy) |
|
Details | ||
| 7/18/2025 | DiaMedica Therapeutics Inc. | DMAC | Maintain | Buy (N/A) |
|
Details | ||
| 5/29/2025 | DiaMedica Therapeutics Inc. | DMAC | Maintain | Buy (Buy) |
|
Details | ||
| 5/27/2025 | Tarsus Pharmaceuticals | TARS | New Coverage | Buy (N/A) |
42.98 (66.17) |
53.96% | Details | |
| 4/4/2025 | Aldeyra Therapeutics | ALDX | Maintain | Buy (Buy) |
|
Details | ||
| 3/19/2025 | DiaMedica Therapeutics Inc. | DMAC | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2024 | Adverum Biotechnologies | ADVM | Maintain | Buy (Buy) |
|
Details | ||
| 10/10/2024 | DiaMedica Therapeutics Inc. | DMAC | Maintain | Buy (Buy) |
|
Details | ||
| 10/7/2024 | DiaMedica Therapeutics Inc. | DMAC | New Coverage | Buy (N/A) |
4.36 (6.28) |
44.04% | Details | |
| 8/13/2024 | Adverum Biotechnologies | ADVM | Maintain | Buy (N/A) |
|
Details | ||
| 4/30/2024 | Adverum Biotechnologies | ADVM | New Coverage | Buy (N/A) |
9.53 (4.29) |
-54.98% | Details | |
| 4/2/2024 | Aldeyra Therapeutics | ALDX | New Coverage | Buy (N/A) |
3.27 (1.24) |
-62.08% | Details | |
| 4/27/2022 | Aldeyra Therapeutics | ALDX | New Coverage | Buy (N/A) |
3.33 (3.27) |
-1.8% | Details |
